Mersana Therapeutics Inc.(MRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MRSN Mersana Therapeutics Inc.

Market Closed 11-15 16:00:00 EST

2.21

-0.31

-12.30%

盘后2.21

+0.000.00%

19:23 EST

High2.61	Low2.21	Vol1.01M
Open2.53	D1 Closing2.52	Amplitude16.07%
Mkt Cap273.01M	Tradable Cap160.45M	Total Shares123.53M
T/O2.35M	T/O Rate1.39%	Tradable Shares72.60M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"MRSN","market":"US","secType":"STK","nameCN":"Mersana Therapeutics Inc.","latestPrice":2.21,"timestamp":1731704400000,"preClose":2.52,"halted":0,"volume":1010218,"hourTrading":{"tag":"盘后","latestPrice":2.21,"preClose":2.21,"latestTime":"19:23 EST","volume":367,"amount":809.61,"timestamp":1731716612870},"delay":0,"floatShares":72603267,"shares":123532909,"eps":-0.612564,"marketStatus":"Market Closed","change":-0.31,"latestTime":"11-15 16:00:00 EST","open":2.53,"high":2.61,"low":2.205,"amount":2346117.150366,"amplitude":0.160714,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.612564,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1731920400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1498622400000,"exchange":"NASDAQ","adjPreClose":2.52,"preHourTrading":{"tag":"盘前","latestPrice":2.57,"preClose":2.52,"latestTime":"09:26 EST","volume":3873,"amount":9798.0617994,"timestamp":1731680764331},"postHourTrading":{"tag":"盘后","latestPrice":2.21,"preClose":2.21,"latestTime":"19:23 EST","volume":367,"amount":809.61,"timestamp":1731716612870},"volumeRatio":0.48188838879952817,"impliedVol":1.4304,"impliedVolPercentile":0.7897},"requestUrl":"/m/hq/s/MRSN/tweets","defaultTab":"tweets","newsList":[{"id":"2483651323","title":"Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Cabaletta Bio (CABA) and Mersana Therapeutics (MRSN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483651323","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483651323?lang=en_us&edition=fundamental","pubTime":"2024-11-15 18:31","pubTimestamp":1731666669,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ACELYRIN, INC. (SLRN – Research Report), Cabaletta...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-acelyrin-inc-slrn-cabaletta-bio-caba-and-mersana-therapeutics-mrsn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-acelyrin-inc-slrn-cabaletta-bio-caba-and-mersana-therapeutics-mrsn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CABA","BK4139","HCSG","BK4563","BK4137","SLRN","INC","MRSN"],"gpt_icon":0},{"id":"2483871322","title":"Truist Financial Reaffirms Their Buy Rating on Mersana Therapeutics (MRSN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483871322","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483871322?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:19","pubTimestamp":1731586777,"startTime":"0","endTime":"0","summary":"In a report released today, Asthika Goonewardene from Truist Financial reiterated a Buy rating on Mersana Therapeutics (MRSN – Research Report). Th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-reaffirms-their-buy-rating-on-mersana-therapeutics-mrsn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-reaffirms-their-buy-rating-on-mersana-therapeutics-mrsn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRSN"],"gpt_icon":0},{"id":"2483384815","title":"Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2483384815","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483384815?lang=en_us&edition=fundamental","pubTime":"2024-11-14 15:06","pubTimestamp":1731567973,"startTime":"0","endTime":"0","summary":"Cash, Cash Equivalents, and Marketable Securities: $155.2 million at the end of Q3 2024.Net Cash Used in Operating Activities: $8.6 million for Q3 2024, significantly lower than $46.1 million in Q3 2023.Collaboration Revenue: $12.6 million for Q3 2024, up from $7.7 million in Q3 2023.Research and Development Expenses: $14.8 million for Q3 2024, down from $30.5 million in Q3 2023.General and Administrative Expenses: $9.9 million for Q3 2024, down from $12.9 million in Q3 2023.Net Loss: $11.5 million for Q3 2024, compared to $41.7 million in Q3 2023.GuruFocus has detected 8 Warning Signs with MRSN.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Mersana Therapeutics Inc  made significant progress in their Phase I clinical trials for XMT-1660 and XMT-2056, with dose escalation ongoing and no maximum tolerated dose established yet.Mersana's proprietary Dolasynthen platform shows a differentiated tolerability profile, allowing higher dosing","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rbIqWn.xRKR__UFFL_7r2Q--~B/aD0yNDA7dz0yNDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7ab79efcc111fa70ca642d1f71f4c3bc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rbIqWn.xRKR__UFFL_7r2Q--~B/aD0yNDA7dz0yNDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7ab79efcc111fa70ca642d1f71f4c3bc"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mersana-therapeutics-inc-mrsn-q3-070613445.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MRSN"],"gpt_icon":1},{"id":"2483814772","title":"Q3 2024 Mersana Therapeutics Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2483814772","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483814772?lang=en_us&edition=fundamental","pubTime":"2024-11-14 14:32","pubTimestamp":1731565964,"startTime":"0","endTime":"0","summary":"Jason Fredette; Senior VP of Investor Relations & Corporate Communications; Mersana Therapeutics Inc. Martin Huber; President, CEO & Director; Mersana Therapeutics Inc. Mohan Bala; Senior VP & Chief Development Officer; Mersana Therapeutics Inc. Brian DeSchuytner; Senior VP, CFO & COO; Mersana Therapeutics Inc. Thank you, Jason, and good morning, everyone. I'm pleased to report that Mersana made significant progress in the third quarter as we continued to dose escalate in our Phase I clinical trials of both XMT-1660 and XMT-2056. We also achieved multiple milestones in our research collaborations, and we maintained the strength of our balance sheet. These accomplishments position us well as we prepare to disclose initial XMT-1660 clinical data at a company event by the end of this year. XMT-1660 is Mersana's ADC candidate targeting B7-H4 that was developed using Dolasynthen platform with site-specific bioconjugation and a drug-to-antibody ratio of six. We believe it has the opportunity","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q3-2024-mersana-therapeutics-inc-063244652.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","MRSN"],"gpt_icon":0},{"id":"2483836484","title":"Mersana Therapeutics Shares Climb 23% After 3Q Results Beat Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483836484","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483836484?lang=en_us&edition=fundamental","pubTime":"2024-11-14 00:30","pubTimestamp":1731515400,"startTime":"0","endTime":"0","summary":"Shares of Mersana Therapeutics jumped Wednesday after the company's loss narrowed and its third-quarter results topped analysts' expectations.The stock was up 23% to $2.71 in morning trading. For the year, shares are up 16%.The biopharmaceutical company posted a loss of $11.5 million, or nine cents a share, compared with a loss of $41.7 million, or 35 cents a share, a year earlier. Analysts polled by FactSet had expected a loss of 17 cents.The Cambridge, Mass.-based company's revenue rose to $12.6 million from $7.7 million the prior year, above analysts expectations of $7.5 million.Mersana's cash, cash equivalents and marketable securities were $155.2 million as of Sept. 30. The company expects its capital resources will be sufficient to support its operations through 2026.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRSN","BK4139","BK4563","LENZ"],"gpt_icon":0},{"id":"2483880569","title":"Mersana Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483880569","media":"reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483880569?lang=en_us&edition=fundamental","pubTime":"2024-11-13 23:26","pubTimestamp":1731511573,"startTime":"0","endTime":"0","summary":"Mersana Therapeutics Inc reports results for the quarter ended September 30 - Earnings SummaryMersana Therapeutics Inc MRSN.OQ reported a quarterly adjusted loss of 9 cents per share for the quarter e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nL8N3MK22J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRSN"],"gpt_icon":0},{"id":"2483007600","title":"BRIEF-Mersana Therapeutics Provides Business Update And Announces Q3 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483007600","media":"reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483007600?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:28","pubTimestamp":1731504511,"startTime":"0","endTime":"0","summary":"BRIEF-Mersana Therapeutics Provides Business Update And Announces Q3 2024 Financial ResultsNov 13  - Mersana Therapeutics Inc MRSN.O:MERSANA THERAPEUTICS PROVIDES BUSINESS UPDATE AND ANNOUNCES THIRD QUARTER 2024 FINANCIAL RESULTSMERSANA THERAPEUTICS: CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES AS OF SEPTEMBER 30, 2024, WERE $155.2 MILLIONSource text: nGNXbJTT8gFurther company coverage: MRSN.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA5X7XQW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRSN","BK4139","BK4563"],"gpt_icon":0},{"id":"2483250838","title":"Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483250838","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483250838?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:10","pubTimestamp":1731503403,"startTime":"0","endTime":"0","summary":"Mersana Therapeutics, Inc.  came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.35 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 50%. A quarter ago, it was expected that this company would post a loss of $0.18 per share when it actually produced a loss of $0.20, delivering a surprise of -11.11%.Mersana Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $12.6 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 32.82%. This compares to year-ago revenues of $7.7 million. The company has topped consensus revenue estimates just once over the last four quarters.While Mersana Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?Investors should be mindful of t","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/9tpS8u8rAmiEoUItmUZeOA--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/090f58c1efbe3555b861102525e50b39","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/9tpS8u8rAmiEoUItmUZeOA--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/090f58c1efbe3555b861102525e50b39"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mersana-therapeutics-inc-mrsn-reports-131003104.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MRSN"],"gpt_icon":0},{"id":"2483005062","title":"BRIEF-Mersana Therapeutics Q3 EPS USD -0.09","url":"https://stock-news.laohu8.com/highlight/detail?id=2483005062","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483005062?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:01","pubTimestamp":1731499295,"startTime":"0","endTime":"0","summary":"Nov 13 (Reuters) - Mersana Therapeutics Q3 net income USD -11.501 million. * Q3 collaboration revenue USD 12.598 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USD","MRSN","LENZ"],"gpt_icon":0},{"id":"2483005754","title":"Mersana Therapeutics Q3 EPS USD -0.09","url":"https://stock-news.laohu8.com/highlight/detail?id=2483005754","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483005754?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:00","pubTimestamp":1731499250,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nPLX47AB18:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MRSN","BK4139","BK4563"],"gpt_icon":0},{"id":"2483064100","title":"Mersana Therapeutics: Cash, Cash Equivalents & Marketable Securities as of September 30, 2024, Were $155.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2483064100","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483064100?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:00","pubTimestamp":1731499250,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA5X7XQW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MRSN","BK4139","BK4563"],"gpt_icon":0},{"id":"2482573941","title":"Mersana Therapeutics Inc    expected to post a loss of 18 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2482573941","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482573941?lang=en_us&edition=fundamental","pubTime":"2024-11-11 23:38","pubTimestamp":1731339496,"startTime":"0","endTime":"0","summary":"* Mersana Therapeutics Inc     is expected to show a fall in quarterly revenue when it reports  results on November 13 for the period ending September 30 2024   * The Cambridge Massachusetts-based  co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRSN","LENZ"],"gpt_icon":0},{"id":"2481606709","title":"Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481606709","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481606709?lang=en_us&edition=fundamental","pubTime":"2024-11-06 21:00","pubTimestamp":1730898000,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Nov.  06, 2024  (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/06/2975683/0/en/Mersana-Therapeutics-to-Host-Third-Quarter-2024-Conference-Call-on-November-13-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","HST","LENZ","BK4588","MRSN","BK4585","BK4139","BK4218","BK4181"],"gpt_icon":1},{"id":"2480887913","title":"Mersana Therapeutics Inc    expected to post a loss of 18 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2480887913","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480887913?lang=en_us&edition=fundamental","pubTime":"2024-11-01 22:41","pubTimestamp":1730472079,"startTime":"0","endTime":"0","summary":"* Mersana Therapeutics Inc     is expected to show a fall in quarterly revenue when it reports  results on November 5 (estimated) for the period ending September 30 2024   * The Cambridge Massachusett","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRSN","LENZ"],"gpt_icon":0},{"id":"2474985714","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2474985714","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474985714?lang=en_us&edition=fundamental","pubTime":"2024-10-10 19:55","pubTimestamp":1728561300,"startTime":"0","endTime":"0","summary":"10X Genomics  shares slumped 26% pre-bell Thursday after the company reported preliminary Q3 sales that trailed analysts' projections.E2open Parent Holdings  shares dropped 22% after the company reported lower fiscal Q2 revenue and cut its full-year revenue guidance.Mersana Therapeutics  shares retreated 21%, adding to Wednesday's 5.5% loss.Indivior  shares fell 17% after the company lowered its fiscal year 2024 revenue guidance.Price: 15.39, Change: -5.42, Percent Change: -26.05","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4548","BK4121","INDV","BK4588","TXG","BK4023","BK4563","ETWO","LU1861559042.SGD","BK4007","BK4585","LU1861558580.USD","MRSN"],"gpt_icon":0},{"id":"2467881967","title":"Truist Financial Remains a Buy on Mersana Therapeutics (MRSN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2467881967","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467881967?lang=en_us&edition=fundamental","pubTime":"2024-09-16 19:16","pubTimestamp":1726485381,"startTime":"0","endTime":"0","summary":"In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report). Th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-remains-a-buy-on-mersana-therapeutics-mrsn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-remains-a-buy-on-mersana-therapeutics-mrsn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4563","MRSN"],"gpt_icon":0},{"id":"2466543699","title":"Truist Financial Releases a Buy Rating on Mersana Therapeutics (MRSN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2466543699","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466543699?lang=en_us&edition=fundamental","pubTime":"2024-09-10 19:16","pubTimestamp":1725966988,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Asthika Goonewardene assigned a Buy rating to the stock today. The company’s shares closed yesterday at $1.50. According t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-releases-a-buy-rating-on-mersana-therapeutics-mrsn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-releases-a-buy-rating-on-mersana-therapeutics-mrsn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRSN"],"gpt_icon":0},{"id":"2459127995","title":"Mersana Therapeutics Is Maintained at Neutral by Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2459127995","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459127995?lang=en_us&edition=fundamental","pubTime":"2024-08-14 19:51","pubTimestamp":1723636260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MRSN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 14, 2024 07:51 ET (11:51 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRSN","LENZ"],"gpt_icon":0},{"id":"2459122909","title":"Truist Financial Issues a Buy Rating on Mersana Therapeutics (MRSN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2459122909","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459122909?lang=en_us&edition=fundamental","pubTime":"2024-08-14 19:28","pubTimestamp":1723634932,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Asthika Goonewardene assigned a Buy rating to the stock today. The company’s shares closed yesterday at $1.35. According t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-issues-a-buy-rating-on-mersana-therapeutics-mrsn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-issues-a-buy-rating-on-mersana-therapeutics-mrsn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRSN"],"gpt_icon":0},{"id":"2459848154","title":"Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459848154","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459848154?lang=en_us&edition=fundamental","pubTime":"2024-08-14 03:08","pubTimestamp":1723576086,"startTime":"0","endTime":"0","summary":"Unfortunately for some shareholders, the Mersana Therapeutics, Inc. ( NASDAQ:MRSN ) share price has dived 32% in the...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrsn/mersana-therapeutics/news/investors-dont-see-light-at-end-of-mersana-therapeutics-incs-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MRSN","IE00BKPKM429.USD",".IXIC","ISBC","PSQ","QLD","BK4112","MNQmain","SQQQ","BK4585","QID","NQmain","LU2210150020.SGD","LU2210149790.SGD","BK4139","NDAQ","TQQQ","BK4563","LU2095319765.USD","BK4211","BK4588"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.mersana.com","stockEarnings":[{"period":"1week","weight":-0.1401},{"period":"1month","weight":0.0474},{"period":"3month","weight":0.687},{"period":"6month","weight":-0.1905},{"period":"1year","weight":0.4351},{"period":"ytd","weight":-0.0474}],"compareEarnings":[{"period":"1week","weight":-0.0208},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0567},{"period":"6month","weight":0.1063},{"period":"1year","weight":0.301},{"period":"ytd","weight":0.2324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.019423},{"month":2,"riseRate":0.571429,"avgChangeRate":0.173916},{"month":3,"riseRate":0,"avgChangeRate":-0.165787},{"month":4,"riseRate":0.428571,"avgChangeRate":0.027646},{"month":5,"riseRate":0.428571,"avgChangeRate":0.275375},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.078008},{"month":7,"riseRate":0.25,"avgChangeRate":-0.160523},{"month":8,"riseRate":0.5,"avgChangeRate":0.058223},{"month":9,"riseRate":0.25,"avgChangeRate":-0.095374},{"month":10,"riseRate":0.25,"avgChangeRate":-0.038972},{"month":11,"riseRate":0.625,"avgChangeRate":0.215079},{"month":12,"riseRate":0.428571,"avgChangeRate":0.053714}],"exchange":"NASDAQ","name":"Mersana Therapeutics Inc.","nameEN":"Mersana Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mersana Therapeutics Inc.(MRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mersana Therapeutics Inc.(MRSN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mersana Therapeutics Inc.,MRSN,Mersana Therapeutics Inc.股票,Mersana Therapeutics Inc.股票老虎,Mersana Therapeutics Inc.股票老虎国际,Mersana Therapeutics Inc.行情,Mersana Therapeutics Inc.股票行情,Mersana Therapeutics Inc.股价,Mersana Therapeutics Inc.股市,Mersana Therapeutics Inc.股票价格,Mersana Therapeutics Inc.股票交易,Mersana Therapeutics Inc.股票购买,Mersana Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mersana Therapeutics Inc.(MRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mersana Therapeutics Inc.(MRSN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction